Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Incyte's Business Segments
Incyte's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 1,216
Regions Reported
2
Revenue Share by Reportable Segment - Q2 FY2025
- Reportable100%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 1,216 | 100% |
Revenue Share by Region - Q2 FY2025
- Europe6.5%
- Other Countries0.4%
Revenue by Geographic Region - Q2 FY2025
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Europe | $ 79 | 6.5% |
| Other Countries | $ 4 | 0.4% |
Revenue by Product & Service Category - Q2 FY2025
- Product87.2%
- JAKAFI62.8%
- OPZELURA13.5%
- Royalty12.4%
- Jakavi Royalty Revenues9%
- NIKTIMVO3%
- Olumiant Royalty Revenues2.8%
- ICLUSIG2.7%
- MINJUVI/MONJUVI2.6%
- PEMAZYRE1.8%
- ZYNYZ0.7%
- Tabrecta Royalty Revenues0.5%
- Milestone and contract revenues0.4%
- Other product royalty revenues0.1%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 1,059 | 87.2% |
| JAKAFI | $ 764 | 62.8% |
| OPZELURA | $ 164 | 13.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Incyte
Incyte Corporation is a pioneering biopharmaceutical company established in 1991 and is headquartered in Wilmington, Delaware, USA. The company has made a significant impact in the biopharmaceutical landscape with a primary focus on the discovery, development, and commercialization of revolutionary therapeutics aimed at addressing various serious medical conditions, particularly cancer and autoimmune disorders.
Overview and Mission
Incytes mission revolves around harnessing specialized knowledge and innovative science to expedite the availability of medicines that can substantially improve patient outcomes. Central to this mission is a commitment to extending and improving the quality of life for patients with severe diseases. The company aims to translate basic science into meaningful therapies through its dedicated research and commercial efforts.
Core Divisions
Incyte operates through two main divisions:
1. Research and Development (R&D): This division is vital to the company’s legacy, focusing on pioneering drug discovery and development. Incytes R&D efforts are concentrated on several strategic areas:
- Small Molecule Drug Discovery: This involves the creation of small molecules that can interfere with biological processes, offering treatment options for complex diseases.
- Immunology and Inflammation: The company explores innovative pathways to manipulate the immune response, targeting chronic inflammatory and autoimmune diseases.
- Oncology: A significant focus area, where Incyte works on discovering targeted therapies that can improve the management of various cancers.
2. Commercial: Incytes commercial division is responsible for bringing these developed therapeutics to market. The team employs strategic marketing and sales efforts to ensure that both healthcare professionals and patients are informed about the available therapies. This division also monitors post-marketing aspects to ensure drug efficacy and safety.
Notable Products and Pipeline
One of Incytes hallmark achievements is the development of Jakafi (Ruxolitinib), the first FDA-approved medication for polycythemia vera (PV) and myelofibrosis. This breakthrough therapy has significantly transformed patient care, demonstrating the ability to alleviate symptoms and prolong survival among those afflicted with these conditions. Jakafi represents a landmark achievement in the field of oncology and hematology.
Additionally, Incyte has been developing other notable drugs:
- Olumiant (baricitinib): A JAK inhibitor co-developed with Eli Lilly and Company, primarily used for the treatment of rheumatoid arthritis. Recent studies have also investigated its utility in other indications, including COVID-19.
- Epacadostat (INCMGA0012): A novel IDO1 inhibitor designed to modulate the immune response against tumors. This drug is currently being developed in collaboration with Merck & Co. showcasing Incytes dedication to cutting-edge cancer immunotherapy research.
The company maintains a broad pipeline of drugs that spans multiple phases of clinical development, which demonstrates its innovation capacity and commitment to improving patient care.
Research Collaborations
Incyte actively pursues partnerships and collaborations with academic institutions, research organizations, and other biopharmaceutical companies to advance its drug discovery initiatives. This collaborative approach not only enhances the firm’s innovative capabilities but also aids in de-risking the drug development process. Incyte invests significantly in cutting-edge technologies that bolster its research productivity, from precision medicine approaches to advanced genomic studies.
Recognition and Achievements
The impact of Incytes work has not gone unrecognized. The company has garnered various accolades for its exemplary contributions to healthcare. In 2020, it was ranked among the 100 Best Companies to Work For in Americaby Fortune Magazine, highlighting its commitment to a positive work environment and corporate culture. Furthermore, the Lasker-DeBakey Clinical Medical Research Award was awarded to the company in 2018 for its innovative work on Jakafi, underscoring the profound influence of this treatment in clinical practice.
Conclusion
Incyte Corporation stands out as a leading entity in the biopharmaceutical sector, committed to the discovery and commercialization of therapies that address complex and serious health conditions. With a rich legacy of innovation, a robust pipeline of promising drugs, and a collaborative approach to research, Incyte is well-equipped to remain at the forefront of medical advancements in the biopharmaceutical landscape. The company’s ongoing efforts in research, development, and patient care illustrate its dedication to making a substantial impact on the lives of patients around the globe.
Overview and Mission
Incytes mission revolves around harnessing specialized knowledge and innovative science to expedite the availability of medicines that can substantially improve patient outcomes. Central to this mission is a commitment to extending and improving the quality of life for patients with severe diseases. The company aims to translate basic science into meaningful therapies through its dedicated research and commercial efforts.
Core Divisions
Incyte operates through two main divisions:
1. Research and Development (R&D): This division is vital to the company’s legacy, focusing on pioneering drug discovery and development. Incytes R&D efforts are concentrated on several strategic areas:
- Small Molecule Drug Discovery: This involves the creation of small molecules that can interfere with biological processes, offering treatment options for complex diseases.
- Immunology and Inflammation: The company explores innovative pathways to manipulate the immune response, targeting chronic inflammatory and autoimmune diseases.
- Oncology: A significant focus area, where Incyte works on discovering targeted therapies that can improve the management of various cancers.
2. Commercial: Incytes commercial division is responsible for bringing these developed therapeutics to market. The team employs strategic marketing and sales efforts to ensure that both healthcare professionals and patients are informed about the available therapies. This division also monitors post-marketing aspects to ensure drug efficacy and safety.
Notable Products and Pipeline
One of Incytes hallmark achievements is the development of Jakafi (Ruxolitinib), the first FDA-approved medication for polycythemia vera (PV) and myelofibrosis. This breakthrough therapy has significantly transformed patient care, demonstrating the ability to alleviate symptoms and prolong survival among those afflicted with these conditions. Jakafi represents a landmark achievement in the field of oncology and hematology.
Additionally, Incyte has been developing other notable drugs:
- Olumiant (baricitinib): A JAK inhibitor co-developed with Eli Lilly and Company, primarily used for the treatment of rheumatoid arthritis. Recent studies have also investigated its utility in other indications, including COVID-19.
- Epacadostat (INCMGA0012): A novel IDO1 inhibitor designed to modulate the immune response against tumors. This drug is currently being developed in collaboration with Merck & Co. showcasing Incytes dedication to cutting-edge cancer immunotherapy research.
The company maintains a broad pipeline of drugs that spans multiple phases of clinical development, which demonstrates its innovation capacity and commitment to improving patient care.
Research Collaborations
Incyte actively pursues partnerships and collaborations with academic institutions, research organizations, and other biopharmaceutical companies to advance its drug discovery initiatives. This collaborative approach not only enhances the firm’s innovative capabilities but also aids in de-risking the drug development process. Incyte invests significantly in cutting-edge technologies that bolster its research productivity, from precision medicine approaches to advanced genomic studies.
Recognition and Achievements
The impact of Incytes work has not gone unrecognized. The company has garnered various accolades for its exemplary contributions to healthcare. In 2020, it was ranked among the 100 Best Companies to Work For in Americaby Fortune Magazine, highlighting its commitment to a positive work environment and corporate culture. Furthermore, the Lasker-DeBakey Clinical Medical Research Award was awarded to the company in 2018 for its innovative work on Jakafi, underscoring the profound influence of this treatment in clinical practice.
Conclusion
Incyte Corporation stands out as a leading entity in the biopharmaceutical sector, committed to the discovery and commercialization of therapies that address complex and serious health conditions. With a rich legacy of innovation, a robust pipeline of promising drugs, and a collaborative approach to research, Incyte is well-equipped to remain at the forefront of medical advancements in the biopharmaceutical landscape. The company’s ongoing efforts in research, development, and patient care illustrate its dedication to making a substantial impact on the lives of patients around the globe.
Incyte Corporation is a prominent player in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of innovative therapeutic solutions primarily aimed at treating cancers and autoimmune disorders. The organization is divided into two main segments: Products and Collaborations.
Segments
1. Products: This segment includes a variety of therapeutic products that Incyte has developed and brought to market. The focus is primarily on treatments for cancer and autoimmune disorders, showcasing Incytes commitment to addressing significant medical needs.
2. Collaborations: Incyte engages in partnerships with other pharmaceutical companies to leverage combined expertise, share resources, and utilize innovative technologies. These collaborations are crucial for accelerating the development and commercialization of new therapies, thereby expanding Incytes drug portfolio and reach in the market.
Products
1. Jakafi (Ruxolitinib):
- Jakafi is an important FDA-approved medication that targets specific patient populations suffering from myeloproliferative neoplasms. It is indicated for adult patients with polycythemia vera (PV) who have not responded adequately to previous treatments with hydroxyurea or cannot tolerate this medication. Additionally, it is prescribed for adults with myelofibrosis, a rare type of blood cancer that affects bone marrow. As a Janus kinase (JAK) inhibitor, Jakafi works by modulating the JAK pathway, helping to alleviate symptoms and enhance the quality of life for patients.
2. Iclusig (Ponatinib):
- Iclusig is an FDA-approved treatment designed for specific types of leukemia, particularly Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). As a kinase inhibitor, Iclusig effectively blocks the action of certain proteins that promote the proliferation of cancer cells, making it a viable option for patients who do not respond satisfactorily to other treatments.
3. Pemazyre (Pemigatinib):
- Pemazyre is a targeted therapy approved for adult patients with cholangiocarcinoma, a rare and challenging cancer that originates in the bile ducts. It is specifically indicated for patients whose tumors exhibit particular genetic characteristics, such as FGFR2 fusions or rearrangements. By inhibiting the fibroblast growth factor receptor (FGFR), Pemazyre aims to improve treatment outcomes for patients facing this complex type of cancer.
4. Additional Products: Incyte has a robust pipeline that includes various other investigational therapies targeting a range of malignancies and autoimmune conditions, thus reinforcing the companys commitment to expanding treatment options for challenging diseases.
Collaborations
1. Eli Lilly:
- Incyte collaborates with Eli Lilly to co-develop and commercialize baricitinib, a medication indicated for treating rheumatoid arthritis. This partnership combines the strengths of both companies in the creation of effective therapies for autoimmune diseases.
2. Novartis:
- Incyte worked closely with Novartis during the discovery and development of ruxolitinib (Jakafi), marking a significant collaboration that highlights the importance of synergy in drug development. This partnership showcases how shared expertise can lead to groundbreaking treatments.
3. Merus:
- In collaboration with Merus, Incyte is advancing several bispecific antibody programs aimed at tackling multiple pathways associated with diseases, particularly in oncology. This collaboration is vital for the advancement of innovative therapeutic options that could improve patient outcomes in cancer care.
4. MorphoSys:
- Incyte and MorphoSys have partnered to develop and commercialize tafasitamab, which is currently under evaluation for the treatment of certain B-cell lymphomas. This collaboration leverages the complementary strengths of both companies in monoclonal antibody therapy development to address unmet medical needs.
Services
In addition to its core therapeutic offerings and collaborative initiatives, Incyte Corporation extends a range of services that facilitate patient care and support drug development:
1. Patient Support Programs:
- Incyte offers comprehensive support programs for patients using its medications. These programs include educational materials, adherence support, and enhanced connectivity to healthcare professionals, empowering patients to manage their conditions effectively.
2. Medical Information and Access/Reimbursement Support:
- The company furnishes extensive medical information services to healthcare providers and patients, ensuring they have the necessary information about Incyte products. Furthermore, Incyte supports patients in navigating the complexities of access and reimbursement, reducing hurdles to obtaining their medications.
3. Research and Development Services:
- Incytes Discovery and Early Development group provides research and development expertise to external biopharmaceutical companies. Services include scientific support in areas such as lead optimization, drug metabolism, and pharmacokinetics, which are crucial for successful drug development.
4. Clinical Development Team:
- Incyte’s clinical development team is responsible for conducting thorough clinical trials that assess the safety and efficacy of new drugs and therapeutics. This pivotal function ensures compliance with regulatory standards and aims to deliver significant benefits to patients suffering from various conditions.
Through its diverse segments, products, collaborations, and services, Incyte Corporation is positioned as a leader in the biopharmaceutical field, dedicated to advancing healthcare via innovation, partnership, and a patient-centric approach.
Segments
1. Products: This segment includes a variety of therapeutic products that Incyte has developed and brought to market. The focus is primarily on treatments for cancer and autoimmune disorders, showcasing Incytes commitment to addressing significant medical needs.
2. Collaborations: Incyte engages in partnerships with other pharmaceutical companies to leverage combined expertise, share resources, and utilize innovative technologies. These collaborations are crucial for accelerating the development and commercialization of new therapies, thereby expanding Incytes drug portfolio and reach in the market.
Products
1. Jakafi (Ruxolitinib):
- Jakafi is an important FDA-approved medication that targets specific patient populations suffering from myeloproliferative neoplasms. It is indicated for adult patients with polycythemia vera (PV) who have not responded adequately to previous treatments with hydroxyurea or cannot tolerate this medication. Additionally, it is prescribed for adults with myelofibrosis, a rare type of blood cancer that affects bone marrow. As a Janus kinase (JAK) inhibitor, Jakafi works by modulating the JAK pathway, helping to alleviate symptoms and enhance the quality of life for patients.
2. Iclusig (Ponatinib):
- Iclusig is an FDA-approved treatment designed for specific types of leukemia, particularly Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). As a kinase inhibitor, Iclusig effectively blocks the action of certain proteins that promote the proliferation of cancer cells, making it a viable option for patients who do not respond satisfactorily to other treatments.
3. Pemazyre (Pemigatinib):
- Pemazyre is a targeted therapy approved for adult patients with cholangiocarcinoma, a rare and challenging cancer that originates in the bile ducts. It is specifically indicated for patients whose tumors exhibit particular genetic characteristics, such as FGFR2 fusions or rearrangements. By inhibiting the fibroblast growth factor receptor (FGFR), Pemazyre aims to improve treatment outcomes for patients facing this complex type of cancer.
4. Additional Products: Incyte has a robust pipeline that includes various other investigational therapies targeting a range of malignancies and autoimmune conditions, thus reinforcing the companys commitment to expanding treatment options for challenging diseases.
Collaborations
1. Eli Lilly:
- Incyte collaborates with Eli Lilly to co-develop and commercialize baricitinib, a medication indicated for treating rheumatoid arthritis. This partnership combines the strengths of both companies in the creation of effective therapies for autoimmune diseases.
2. Novartis:
- Incyte worked closely with Novartis during the discovery and development of ruxolitinib (Jakafi), marking a significant collaboration that highlights the importance of synergy in drug development. This partnership showcases how shared expertise can lead to groundbreaking treatments.
3. Merus:
- In collaboration with Merus, Incyte is advancing several bispecific antibody programs aimed at tackling multiple pathways associated with diseases, particularly in oncology. This collaboration is vital for the advancement of innovative therapeutic options that could improve patient outcomes in cancer care.
4. MorphoSys:
- Incyte and MorphoSys have partnered to develop and commercialize tafasitamab, which is currently under evaluation for the treatment of certain B-cell lymphomas. This collaboration leverages the complementary strengths of both companies in monoclonal antibody therapy development to address unmet medical needs.
Services
In addition to its core therapeutic offerings and collaborative initiatives, Incyte Corporation extends a range of services that facilitate patient care and support drug development:
1. Patient Support Programs:
- Incyte offers comprehensive support programs for patients using its medications. These programs include educational materials, adherence support, and enhanced connectivity to healthcare professionals, empowering patients to manage their conditions effectively.
2. Medical Information and Access/Reimbursement Support:
- The company furnishes extensive medical information services to healthcare providers and patients, ensuring they have the necessary information about Incyte products. Furthermore, Incyte supports patients in navigating the complexities of access and reimbursement, reducing hurdles to obtaining their medications.
3. Research and Development Services:
- Incytes Discovery and Early Development group provides research and development expertise to external biopharmaceutical companies. Services include scientific support in areas such as lead optimization, drug metabolism, and pharmacokinetics, which are crucial for successful drug development.
4. Clinical Development Team:
- Incyte’s clinical development team is responsible for conducting thorough clinical trials that assess the safety and efficacy of new drugs and therapeutics. This pivotal function ensures compliance with regulatory standards and aims to deliver significant benefits to patients suffering from various conditions.
Through its diverse segments, products, collaborations, and services, Incyte Corporation is positioned as a leader in the biopharmaceutical field, dedicated to advancing healthcare via innovation, partnership, and a patient-centric approach.